Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease.

Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease.

Čájet eará veršuvnnaid (1)

The overlapping clinical features of relapsing remitting multiple sclerosis (RRMS), aquaporin-4 (AQP4)-antibody (Ab) neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein (MOG)-Ab disease mean that detection of disease specific serum antibodies is the gold standard...

Bibliográfalaš dieđut
Váldodahkkit:	Jurynczyk, M, Probert, F, Yeo, T, Tackley, G, Claridge, T, Cavey, A, Woodhall, M, Arora, S, Winkler, T, Schiffer, E, Vincent, A, DeLuca, G, Sibson, N, Leite, M, Waters, P, Anthony, D, Palace, J
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	BioMed Central 2017

Geahča maid

Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease
Dahkki: Jurynczyk, M, et al.
Almmustuhtton: (2017)

Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease
Dahkki: Maciej Jurynczyk, et al.
Almmustuhtton: (2017-12-01)

Distinguishing the brain MRI features of MS, AQP4-and MOG-antibody disease.
Dahkki: Jurynczyk, M, et al.
Almmustuhtton: (2016)

Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease
Dahkki: Juryńczyk, M, et al.
Almmustuhtton: (2016)

RELAPSING AQP4 ANTIBODY NEGATIVE NMO WITH MOG ANTIBODIES
Dahkki: Elsone, L, et al.
Almmustuhtton: (2014)

Classifying the antibody-negative NMO syndromes: Clinical, imaging, and metabolomic modeling
Dahkki: Yeo, T, et al.
Almmustuhtton: (2019)

Factors associated with fatigue in CNS inflammatory diseases with AQP4 and MOG antibodies
Dahkki: Yeo, T, et al.
Almmustuhtton: (2020)

Factors associated with fatigue in CNS inflammatory diseases with AQP4 and MOG antibodies
Dahkki: Tianrong Yeo, et al.
Almmustuhtton: (2020-03-01)

Disease course and disability outcomes in MOG-antibody disease in the UK
Dahkki: Jurynczyk, M, et al.
Almmustuhtton: (2017)

Clinical presentation and prognosis in MOG-antibody disease: a UK study
Dahkki: Jurynczyk, M, et al.
Almmustuhtton: (2017)

International multicenter examination of MOG antibody assays
Dahkki: Reindl, M, et al.
Almmustuhtton: (2020)

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
Dahkki: Sato, D, et al.
Almmustuhtton: (2014)

Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS
Dahkki: Waters, P, et al.
Almmustuhtton: (2015)

Recurrent optic neuritis associated with MOG antibody seropositivity
Dahkki: Chang, T, et al.
Almmustuhtton: (2017)

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
Dahkki: Kezuka, T, et al.
Almmustuhtton: (2014)

A Longitudinal Comparison of the Recovery Patterns of Optic Neuritis with MOG Antibody-Seropositive and AQP4 Antibody-Seropositive or -Seronegative for Both Antibodies
Dahkki: Lin Zhou, et al.
Almmustuhtton: (2022-01-01)

Value of Area Postrema Syndrome in Differentiating Adults With AQP4 vs. MOG Antibodies
Dahkki: Jae-Won Hyun, et al.
Almmustuhtton: (2020-06-01)

Prevalence of serum MOG antibody and AQP4 antibody in optic neuritis after SARS-CoV-2 infection
Dahkki: Chuan-bin Sun
Almmustuhtton: (2023-11-01)

An international multicentre validation experiment for MOG antibodies
Dahkki: Reindl, M, et al.
Almmustuhtton: (2018)

Features of the diagnosis and treatment of patients with AQP-4-positive neuromyelitis optica and MOG antibody disease
Dahkki: V. E. Avdeeva, et al.
Almmustuhtton: (2021-11-01)

MOG-IgG1 antibodies in children
Dahkki: Waters, P, et al.
Almmustuhtton: (2018)

A 41-year-old woman with acute weakness and encephalopathy associated with MOG antibodies.
Dahkki: Morris, K, et al.
Almmustuhtton: (2015)

Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up.
Dahkki: Piccolo, L, et al.
Almmustuhtton: (2016)

MOG cell-based assay detects non-MS patients with inflammatory neurologic disease
Dahkki: Waters, P, et al.
Almmustuhtton: (2015)

Predictors of relapse in MOG antibody associated disease: a cohort study
Dahkki: Saif Huda, et al.
Almmustuhtton: (2021-11-01)

Case report: Satralizumab as an adjunctive therapy for AQP-4 antibody and MOG antibody dual-negative optic neuritis in a third-trimester pregnancy case
Dahkki: Chuanbin Sun, et al.
Almmustuhtton: (2024-12-01)

Different immunological mechanisms between AQP4 antibody-positive and MOG antibody-positive optic neuritis based on RNA sequencing analysis of whole blood
Dahkki: Xuelian Chen, et al.
Almmustuhtton: (2023-03-01)

No strong HLA association with MOG antibody disease in the UK population
Dahkki: Grant-Peters, M, et al.
Almmustuhtton: (2021)

Chronic neuropathic pain severity is determined by lesion level in aquaporin 4-antibody-positive myelitis
Dahkki: Tackley, G, et al.
Almmustuhtton: (2016)

MOG encephalomyelitis: international recommendations on diagnosis and antibody testing
Dahkki: Jarius, S, et al.
Almmustuhtton: (2018)

Corrigendum: Different immunological mechanisms between AQP4 antibody-positive and MOG antibody-positive optic neuritis based on RNA sequencing analysis of whole blood
Dahkki: Xuelian Chen, et al.
Almmustuhtton: (2023-08-01)

MOG antibody associated disorder (MOGAD)
Dahkki: Lilley Kate, et al.
Almmustuhtton: (2021-01-01)

Epilepsy in patients with MOG antibody disease
Dahkki: Varvara E. Avdeeva, et al.
Almmustuhtton: (2021-10-01)

No strong HLA association with MOG antibody disease in the UK population
Dahkki: Melissa Grant‐Peters, et al.
Almmustuhtton: (2021-07-01)

Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies
Dahkki: Elisabeth Maillart, et al.
Almmustuhtton: (2020-04-01)

Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method
Dahkki: Luca Bollo, et al.
Almmustuhtton: (2021-03-01)

Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies.
Dahkki: Kaneko, K, et al.
Almmustuhtton: (2016)

Understanding MOG antibody-associated disease in Brazil
Dahkki: Dagoberto Callegaro, et al.
Almmustuhtton: (2023-11-01)

AQP4 antibody assay sensitivity comparison in the era of the 2015 diagnostic criteria for NMOSD
Dahkki: Prain, K, et al.
Almmustuhtton: (2019)

Pediatric MOG antibody-positive encephalitis with normal brain magnetic resonance imaging: a new spectrum associated with MOG antibodies?
Dahkki: Yan Jiang, et al.
Almmustuhtton: (2025-02-01)